{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:37:37Z","timestamp":1776940657018,"version":"3.51.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Transarterial radioembolization (TARE) is a therapeutic option for patients with liver tumors. However, factors responsible for treatment resistance in TARE remain largely unknown. In this study, we aimed to investigate the role of hypoxia in the treatment response of liver tumors using <jats:sup>18<\/jats:sup>F-FMISO PET imaging before TARE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>This single-center prospective study included 25 patients with primary or metastatic liver tumors imaged with <jats:sup>18<\/jats:sup>F-FMISO PET\/CT before TARE and treated with <jats:sup>90<\/jats:sup>Y resin microspheres. Posttreatment response was assessed with <jats:sup>18<\/jats:sup>F-FDG PET imaging. Hypoxia status was evaluated by calculating the tumor-to-muscle (T\/M) and tumor-to-blood pool (T\/BP) ratios. Absorbed dose metrics were derived from <jats:sup>90<\/jats:sup>Y PET\/MRI imaging post-procedure. Lesions were categorized by response as complete responders (CR), partial responders (PR), stable disease (SD), and progressive disease (PD). Statistical analyses included ROC curve analysis, \u03c72 tests, and regression models to determine predictors of treatment response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Among 25 patients (mean age: 60.4 \u00b1 12 y, 56% males), 54 <jats:sup>18<\/jats:sup>F-FDG-avid lesions were evaluated. The median absorbed dose (Dmean) was 114.8 Gy for CR, 98.9 Gy for PR, 56.7 Gy for SD, and 78.3 Gy for PD. Significant differences in Dmean (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.013) and T\/BP ratios (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.011) were observed between responder and nonresponder groups. High Dmean lesions (&gt;89 Gy) had a response rate of 86%, compared with 56% in low Dmean lesions. Hypoxic lesions (T\/BP &gt;1.29) showed a 57% response rate, while non-hypoxic lesions (T\/BP &lt;1.29) showed a 91% response rate. In combined analyses, while non-hypoxic\/high Dmean lesions had the highest response rates (93%), hypoxic\/low-dose had the lowest response rate (39%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In this study, we have observed that both mean absorbed radiation dose and hypoxia status are significant predictors of response to treatment after radioembolization of liver tumors. While larger studies are needed to confirm these findings, this pilot study may pave the way for further personalized treatments to achieve better results for radioembolization.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005918","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T05:00:08Z","timestamp":1745902808000},"page":"e391-e400","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Hypoxia Before Radioembolization Treatment With 18F-FMISO PET"],"prefix":"10.1097","volume":"50","author":[{"given":"Cigdem","family":"Soydal","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Ankara University Medical School, Ankara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-9988","authenticated-orcid":false,"given":"Burak","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Sanliurfa Mehmet Akif Inan Research and Education Hospital, Sanliurfa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-7064","authenticated-orcid":false,"given":"Emre Can","family":"Celebioglu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Ankara University Medical School, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-6484","authenticated-orcid":false,"given":"Ecenur","family":"Dursun","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ankara University Medical School, Ankara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-4973","authenticated-orcid":false,"given":"Gizem","family":"Inal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ankara University Medical School, Ankara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuriye Ozlem","family":"Kucuk","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ankara University Medical School, Ankara"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Sadik","family":"Bilgic","sequence":"additional","affiliation":[{"name":"Department of Radiology, Ankara University Medical School, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin Wiley"},{"key":"R2-20250619","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","article-title":"EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.","volume":"49","author":"Weber","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20250619","first-page":"1673","article-title":"Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres","volume":"41","author":"Dancey","year":"2000","journal-title":"J Nucl Med"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.2967\/jnumed.120.255745","article-title":"Dose-Response and Dose-Toxicity Relationships for Glass (90)Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer.","volume":"62","author":"Alsultan","year":"2021","journal-title":"J Nucl Med"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with (90)Y in the SARAH Study.","volume":"296","author":"Hermann","year":"2020","journal-title":"Radiology"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.2967\/jnumed.115.166942","article-title":"Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.","volume":"57","author":"van den Hoven","year":"2016","journal-title":"J Nucl Med"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/HP.0000000000001601","article-title":"Radiation-induced cell death and its mechanisms","volume":"123","author":"Jiao","year":"2022","journal-title":"Health Phys"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"56454","DOI":"10.1021\/acsami.2c14628","article-title":"Prodrug Nanosensitizer Overcomes the Radiation Resistance of Hypoxic Tumor.","volume":"14","author":"Qian","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"R10-20250619","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030610","article-title":"Resistance of Hypoxic Cells to Ionizing Radiation Is Mediated in Part via Hypoxia-Induced Quiescence.","volume":"10","author":"Menegakis","year":"2021","journal-title":"Cells"},{"key":"R11-20250619","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1158\/1078-0432.CCR-0688-3","article-title":"Hypoxia and glucose metabolism in malignant tumorsevaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging","volume":"10","author":"Rajendran","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"568\ufeff","DOI":"10.3390\/molecules25030568","article-title":"Approaches to PET imaging of glioblastoma","volume":"25","author":"Drake","year":"2020","journal-title":"Molecules"},{"key":"R13-20250619","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.3390\/cancers13143449","article-title":"(18)F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy.","volume":"13","author":"Carles","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13014-018-1147-2","article-title":"FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.","volume":"13","author":"Thureau","year":"2018","journal-title":"Radiat Oncol"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/jpm12081245","article-title":"FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer.","volume":"12","author":"Dolezel","year":"2022","journal-title":"J Pers Med"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1097\/RLU.0000000000005323","article-title":"Imaging of Hypoxia in Liver Tumors With 18 F-FMISO PET Before Selective Internal Radiotherapy With 90 Y Microspheres.","volume":"49","author":"Soydal","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the Quantitative Imaging Network","volume":"30","author":"Fedorov","year":"2012","journal-title":"Magn Reson Imaging"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2967\/jnumed.115.165613","article-title":"Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer.","volume":"57","author":"Michl","year":"2016","journal-title":"J Nucl Med"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.2967\/jnumed.112.116426","article-title":"Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.","volume":"54","author":"Fendler","year":"2013","journal-title":"J Nucl Med"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"2445\ufeff","DOI":"10.21105\/joss.02445","article-title":"Extracting, computing and exploring the parameters of statistical models using R","volume":"5","author":"L\u00fcdecke","year":"2020","journal-title":"J Open Source Softw"},{"key":"R27-20250619","first-page":"1775","article-title":"Tumor Hypoxia Detected by (18)F-fluoromisonidazole Positron Emission Tomography (FMISO PET) as a Prognostic Indicator of Radiotherapy (RT).","volume":"38","author":"Tachibana","year":"2018","journal-title":"Anticancer Res"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2967\/jnumed.110.084517","article-title":"Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET\/CT study.","volume":"52","author":"Hugonnet","year":"2011","journal-title":"J Nucl Med"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1007\/s00259-006-0175-6","article-title":"FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.","volume":"33","author":"Zimny","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.112.109330","article-title":"High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.","volume":"54","author":"Okamoto","year":"2013","journal-title":"J Nucl Med"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"e210094","DOI":"10.1148\/rycan.210094","article-title":"Limitations of Fluorine 18 Fluoromisonidazole in Assessing Treatment-induced Tissue Hypoxia after Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Prospective Pilot Study.","volume":"4","author":"Shah","year":"2022","journal-title":"Radiol Imaging Cancer"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.radonc.2015.09.015","article-title":"Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome.","volume":"117","author":"Wiedenmann","year":"2015","journal-title":"Radiother Oncol"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00259-019-04285-9","article-title":"Radiotherapy boost in patients with hypoxic lesions identified by (18)F-FMISO PET\/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].","volume":"46","author":"Vera","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R34-20250619","first-page":"1397","article-title":"Pharmacokinetics of FETNIM: a potential hypoxia marker for PET","volume":"42","author":"Gr\u00f6nroos","year":"2001","journal-title":"J Nucl Med"},{"key":"R35-20250619","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00259-002-1016-x","article-title":"Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.","volume":"30","author":"Lehti\u00f6","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:00:37Z","timestamp":1750341637000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005918"}},"subtitle":["ARTE-MISO Trial"],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005918","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"2024-12-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}